How Has the Fertility Drugs Market Size Evolved in Recent Years?
The fertility drugs market has seen considerable growth due to a variety of factors.
• There has been robust growth in the fertility drugs market size in the past few years. It is projected to increase from a valuation of $3.13 billion in 2024 to reach $3.36 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.3%.
The considerable growth observed in the historical period can be traced back to rising infertility rates, advancements in reproductive healthcare, developments in assisted reproductive technologies (ART), and postponement of childbirth.
What are the Market Size and Expected Growth Rates for the Fertility Drugs Market?
The fertility drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market for fertility drugs is projected to exhibit significant expansion in the coming years, with the expectation to reach $4.39 billion by 2029, reflecting a compound annual growth rate (CAGR) of 6.9%.
This growth trajectory throughout the forecast period can be ascribed to factors such as the increasing elderly population, changes in lifestyle factors, developments in assisted reproductive technologies (ART), and the emergence of personalized medicine. Key upcoming trends during the forecast period encompass advancements in ART, the evolution of ovulation-stimulating drugs, and the progression in hormone treatment.
Which Key Drivers Are Propelling The Fertility Drugs Market's Growth?
The market for fertility medications is expanding due to the growing prevalence of infertility worldwide. Infertility, defined as the failure to become pregnant after 12 months of trying, is primarily treated using fertility drugs. These medications are common for treating infertility in both men and women. Heightened infertility rates are often linked to physiological issues, hormonal imbalances, and lifestyle or environmental factors. Fertility medications play a significant role in managing ovulation cycles in women to treat fertility issues, thereby impacting the sales of these drugs. For example, the Office for National Statistics, a UK-based branch of the UK Statistics Authority, reported in February 2024 that the total fertility rate (TFR) fell to 1.49 children per woman in 2022, a drop from 1.55 in 2021. Consequently, the increasing instances of infertility worldwide are driving the demand for fertility drugs, contributing to the growth of the fertility drug market.
What Are The Key Segments Within The Global Fertility Drugs Market?
The fertility drugs market covered in this report is segmented –
1) By Type Of Drug: Prescription Fertility Drugs, Over-The-Counter Fertility drugs
2) By Route of Administration: Oral, Intravenous, Subcutaneous, Intramuscular
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Prescription Fertility Drugs: Gonadotropins, Clomiphene Citrate, Letrozole, GnRH Agonists, GnRH Antagonists, Progesterone
2) By Over-The-Counter Fertility Drugs: Ovulation Predictor Kits, Fertility Supplements, Fertility Monitors
Pre-Book The Fertility Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Fertility Drugs Industry?
Leading firms in the fertility drugs market are placing their emphasis on the creation of innovative solutions such as peptide-based injectable treatments, with the aim of improving outcomes in reproductive health. These treatments make use of synthetic or natural peptides to stimulate or regulate hormone activity, specifically relating to fertility and reproductive health. As an illustration, Lupin Limited, a company based in India focused on pharmaceuticals, introduced a ganirelix acetate injection in the United States in February 2024. The medication is typically used in conjunction with assisted reproductive technology (ART) protocols to deter premature ovulation as women undergo in vitro fertilization (IVF) during controlled ovarian stimulation. Ganirelix acetate operates as a GnRH antagonist to assist in hormone level regulation, thereby allowing improved control over ovarian stimulation. The launch in the U.S showcases Lupin's continued commitment to the expansion of its product range in the reproductive health arena and its dedication to meeting the needs of those receiving fertility treatments.
Who Are the Key Players In The Fertility Drugs Market?
Major companies operating in the fertility drugs market include:
• Merck & Co.
• Ferring Pharmaceuticals Inc.
• Bayer AG
• Berlex Laboratories Inc.
• Janssen Pharmaceutical Inc.
• Pfizer Inc.
• Novartis AG
• Procter & Gamble Health Limited
• Zydus Lifesciences Limited
• Livzon Pharmaceutical Group Inc.
• Abbott Laboratories
• Sanofi S.A.
• Eli Lilly and Company
• Serono Inc.
• Novagen Healthcare Pvt. Ltd.
• Takeda Pharmaceutical Co. Ltd.
• AstraZeneca plc
• Aurobindo Pharma Ltd.
• Schering-Plough Corporation
• Regeneron Pharmaceuticals Inc.
• F. Hoffmann-La Roche AG
• Vitrolife
• Cook Medical
• Organon Group
• The Cooper Companies Inc.
• Irvine Scientific
• Genea Biomedx
• Mankind Pharma
What Are The Regional Insights Into The Fertility Drugs Market?
North America was the largest region in the fertility drugs market in 2024. The Middle East is expected to be the fastest-growing region in the drugs for infertility market during the forecast period. The regions covered in the fertility drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
